Next Article in Journal
The Role of Medical Image Modalities and AI in the Early Detection, Diagnosis and Grading of Retinal Diseases: A Survey
Previous Article in Journal
Naturally Equipped Urinary Exosomes Coated Poly (2−ethyl−2−oxazoline)−Poly (D, L−lactide) Nanocarriers for the Pre−Clinical Translation of Breast Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Bioprocess Strategies for Vitamin B12 Production by Microbial Fermentation and Its Market Applications

1
Laboratory of Biochemistry, Institut Químic de Sarrià, University Ramon Llull, 08017 Barcelona, Spain
2
HealthTech Bio Actives, S.L.U., 08029 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Bioengineering 2022, 9(8), 365; https://doi.org/10.3390/bioengineering9080365
Submission received: 21 June 2022 / Revised: 27 July 2022 / Accepted: 29 July 2022 / Published: 4 August 2022
(This article belongs to the Section Biochemical Engineering)

Abstract

:
Vitamin B12 is a widely used compound in the feed and food, healthcare and medical industries that can only be produced by fermentation because of the complexity of its chemical synthesis. For this reason, finding better producer strains and optimizing their bioprocesses have been the main focus of industrial producers over the last few decades. In this review, we initially provide a historical overview of vitamin B12 research and the main biosynthetic characteristics of the two microorganism families typically used for its industrial production: several strains of Propionibacterium freudenreichii and strains related to Pseudomonas denitrificans. Later, a complete summary of the current state of vitamin B12 industrial production as well as the main advances and challenges for improving it is detailed, with a special focus on bioprocess optimization, which aims not only to increase production but also sustainability. In addition, a comprehensive list of the most important and relevant patents for the present industrial strains is provided. Finally, the potential applications of vitamin B12 in different markets are discussed.

1. Historical Overview

Vitamin B12, also known as cobalamin, is a water-soluble molecule essential in many organisms’ metabolism. It has a complex structure and an elaborated biosynthesis, with over 30 biotransformation steps [1]. This biosynthetic pathway is only present in some bacteria and archaea, although the phyla capable of synthetizing vitamin B12 are not necessarily interrelated, so mammals, and therefore humans, are unable to synthetize it.
Investigation into vitamin B12 began in the 1920s in connection to an illness firstly described in 1824, pernicious anemia. The main symptoms of this illness included fatigue, weight loss, headaches and, in severe cases, dementia, memory loss, muscle weakness and peripheral neuropathy, which can become lethal without treatment. In 1926, Minot and Murphy demonstrated that patients with pernicious anemia could successfully recover from the condition by a special diet with high amounts of lightly cooked liver and muscle meat [2]. They theorized that the treatment was successful because of an unknown “extrinsic factor” present in animal livers. For this discovery, they were awarded the Nobel Prize in Physiology or Medicine in 1934, although it was more than two decades before the so called “extrinsic factor” was identified and isolated. This occurred in 1948, when two research groups from pharmaceutical companies (Folkers at Merck, Sharp & Dohme, and Smith at Glaxo) isolated, almost at the same time, a cobalt compound from animal livers that was able to cure pernicious anemia on its own [3,4]. A year later, the same compound could also be isolated from other sources, such as milk, beef and several bacterial cultures. This red crystalline octahedral cobalt compound was called vitamin B12. Interestingly, years later, it was discovered that this compound was in fact one of the many isoforms of the cobalamin (Cbl) family, cyanocobalamin (CNCbl), an artificial physiologically inactive form of cobalamin generated in the industrial process of extraction and isolation from the liver. In addition, CNCbl was the first cobalamin isoform whose structure was solved in 1955 by Dorothy Hodgkin [5].
In 1957, the structure of adenosylcobalamin (AdoCbl), one of the two active forms of cobalamin, was also determined by the same group [5]. These discoveries led to Hodgkin being awarded the Nobel Prize in Chemistry in 1960. Two years later, another physiologically active vitamin B12 isoform, methylcobalamin (MetCbl), was discovered. Both AdoCbl and MetCbl were found to act as cofactors in several enzymes and, in the years to come, many MetCbl- and AdoCbl-dependent enzymes were isolated and described. Some of them, such as methionine synthase from Escherichia coli and L-methylmalonyl-CoA mutase from Propionibacterium shermanii, were crystallized [6,7], as well as most of the molecules responsible for vitamin B12 transport in mammals [8,9,10,11,12,13,14,15].
In 1973, after a long study that spanned over a decade, the complete chemical synthesis of vitamin B12 was described by Woodward and colleagues [16]. The process was complex, with over 60 steps, including protection and deprotection reactions, and rendered very low yields, less than 1% [16,17].

2. Structure of Cobalamin Derivatives and Functions as Enzyme Cofactors

Vitamin B12 is the generic name used to designate a family of compounds (cobalamins or Cbl) that share the same common structure: a tetrapyrrolic corrinic ring with a central cobalt atom coordinated to four nitrogen atoms. This scaffold is similar to other prosthetic groups, such as heme in hemoglobin or cytochrome P450. This structure allows the use of the redox state of the central metallic atom, cobalt, allowing the molecule to fulfil its different functions.
As shown in Figure 1, the corrin ring is formed by four pyrrole units (C4H5N), joined on opposite sides by a C-CH3 methylene link, a C-H link on one side and two pyrrole units directly joined, missing the methine bridge between the A and D subunits present in other known porphyrins, such as hemoglobin. This structure differs from those of other, similar molecules in terms of the number and type of side chains, the oxidation state and the central metallic atom.
Besides the four N atoms of the pyrrole units, the central Co ion is linked to two other ligands. The lower ligand is the base 5,6-dimethylbenzimidazole (DMBI) linked with the central Co ion through the N7-atom in α-axial conformation. DMBI is also linked to one of the side chains of the central corrinic structure: its phosphate group joins to an aminopropanol group that is linked to the propionic acid side chain of the pyrrole unit D of the corrinic ring.
Finally, the sixth ligand is linked to Co in the β-axial position. The nature of this chemical group is variable, presenting different physiological and catalytic functions. For example, a 5-deoxyadenosyl group in this position forms adenosylcobalamin (AdoCbl), while a methyl group forms the methylcobalamin (MetCbl) isoform. In fact, the C-Co found in AdoCbl was the first bond of its type described in a biological molecule [18]. Although these two are the isoforms that present physiological activity as cofactors in humans, other forms, such as hydroxocobalamin (OHCbl) or cyanocobalamin (CNCbl), exist, as well as others with less common upper ligands, such as nitritocobalamin (NitCbl), sulfitocobalamin (SulCbl) or glutathionylcobalamin (GlutCbl) [19].
On one hand, MetCbl is a cofactor of several methyltransferases, such as methionine synthase in humans, an important cellular housekeeping enzyme that functions in two major metabolic pathways: the tetrahydrofolate-dependent one-carbon cycle and the final step in the conversion of methionine from homocysteine. On the other hand, AdoCbl is used as a cofactor by several enzymes, mostly mutases, although only one AdoCbl dependent enzyme is found in mammals: L-methylmalonyl-CoA mutase (MMCM), a critical enzyme for propionate catabolism and degradation of odd-chain fatty acids, several amino acids (valine, isoleucine, methionine, threonine) and cholesterol.
As previously stated, AdoCbl and MetCbl are the active cobalamin isoforms, but they are also known to be light sensitive [20,21]. For this reason, the most common commercial form of vitamin B12 is CNCbl instead, which is more stable and readily converted in the body into an active coenzyme form [22].

3. Biosynthesis of Vitamin B12: The Aerobic and Anaerobic Pathways

The discovery of the structure and biological functions of the different vitamin B12 compounds in the 1970s focused the attention of many researchers on the biosynthetic pathways of Cbl-producing organisms. The structural complexity, as it was later established, was due to a large and convoluted biosynthesis that involves more than thirty genes and many enzymatic steps for the “de novo” synthesis of the molecule. This pathway is thought to be exclusive for some bacteria and archaea, as there is no genetic evidence of any eukaryotic organism being capable of producing any isoform of Cbl [1,23].
Although some intermediates were found and isolated earlier [24], it was not until the 1990s that the complete biosynthetic pathway was described in Pseudomonas denitrificans [25]. The genes involved in Cbl synthesis were given the prefix cob and a letter that refers to each gene position in the operon. In the following years, the cob enzymes and cobalamin intermediates of P. denitrificans were characterized and isolated by the French company Rhône-Poulenc Santé, nowadays Sanofi [26].
Later, genes involved in Cbl biosynthesis were characterized in other organisms, such as Bacillus megaterium, Salmonella enterica and the previously studied Propionibacterium freudenreichii. From the beginning, it was clear that the pathway found in the later organisms was similar to the one found in P. denitrificans but genetically different. Key differences included the lack of a monooxygenase and a different cobaltochelatase. Taking this into account, two different pathways for Cbl biosynthesis were established: (i) an aerobic or late cobalt insertion pathway, performed by P. denitrificans [27] and, as it was later discovered, by other microorganisms, such as Ensifer casida and Sinorhizobium meliloti; and (ii) an anaerobic or early cobalt insertion pathway, performed mainly by P. freudenreichii, B. megaterium and S. enterica [28].
Independently of the biosynthetic pathway, tetrapyrrole synthesis begins with the synthesis of 5-aminolaevulinic acid (ALA). Thereafter, ALA conversion to a tetrapyrrolic macrocycle structure is performed by three different enzymatic reactions. First, an ALA dehydratase (EC 4.2.1.24), a Zn2+ and Mg2+-dependent enzyme catalyzes the condensation reaction between two ALA molecules to form porphobilinogen (PBG) [29]. Then, a PBG deamynase (EC 4.3.1.8) polymerizes four molecules of PBG into a linear tetrapyrrole. Finally, a uroporphyrinogen III synthase (EC 4.2.1.75) is able to invert the final pyrrole unit and link it to the first pyrrole unit of the linear tetrapyrrole, forming uroporphyrinogen III, an unsymmetrical hexahydro porphyrin isomer [30]. This molecule is the last intermediate shared with other prosthetic groups, such as heme and chlorophyll groups [31].
The transformation of uroporphyrinogen III to precorrin-2, the first molecule in Figure 2, is catalyzed by an uroporhyrinogen III methyltransferase (EC 2.1.1.107), which requires S-adenosyl-L-methione (SAM) as the methyl donor. More specifically, the enzyme methylates at C-2 of the uroporphyrinogen III forming precorrin I and, after a phototrophic tautomerization, the same enzyme is able to methylate at C-7, obtaining precorrin-2, which is the last common intermediate for coenzyme siroheme, P450 and vitamin B12 [31,32].
The main differences between the aerobic and anaerobic pathways are in the ring contraction and cobalt chelation steps (see Figure 2). On one hand, the ring contraction in the aerobic pathway requires a molecule of oxygen plus a monooxygenase (CobG) to form precorrin-3B, a hydroxylated γ-lactone intermediate that undergoes a masked pinacol rearrangement during the ring contraction, extruding the methylated C20 position. The ring is then totally contracted, and an acetic acid molecule is liberated in the process [28]. On the other hand, the ring contraction takes place at a later stage in the anaerobic pathway when the cobalt has already been inserted in the molecule. This step is catalyzed by the enzyme codified by the cbiH gene, with no molecular oxygen needed. Thereafter, a SAM-dependent methylation takes place at C17, promoting the extrusion of the already methylated C20 position and forming a δ-lactone ring [28].
Cobalt chelation is also very different in both pathways. In the aerobic pathway, there is a “late” insertion of the cobalt atom once the ring has been fully contracted. This insertion is catalyzed by an ATP-dependent multienzyme complex (cobNST) in the presence of magnesium [28,33]. In the anaerobic pathway, this step takes place at an earlier point on the route, when a cobalt chelatase, encoded by either cbiX or cbiK genes, catalyzes the cobalt insertion with the ring still in a non-contracted state [28].
In addition, independently of the biosynthetic pathway of the corrin ring, DMBI is produced separately to be later attached in α-axial conformation. The lower ligand synthesis has been described recently and also presents two clearly differentiated routes (the aerobic and the anaerobic pathway), depending on the needs of oxygen.
On one hand, the aerobic biosynthesis of DMBI is catalyzed by the 5,6-dimethylbenzimidazole synthase BluB (EC 1.13.11.79), which performs the fragmentation and contraction of the bound flavin mononucleotide cofactor and the cleavage of the ribityl tail to form DMBI and D-erythrose 4-phosphate in the presence of molecular oxygen. Later, the phosphoribosyltransferase CobU/T (EC 2.4.2.21) introduces the DMBI via a nucleophilic substitution reaction [34]. This pathway was firstly described for S. meliloti [35] and later found in the majority of Cbl-producing bacteria [36], including the two most important industrial producers, P. freudenreichii [37] and P. denitrificans [38]. This fact highlighted the incapacity of P. freudenreichii to completely produce Cbl anaerobically without any external addition of DMBI.
On the other hand, the anaerobic biosynthesis of DMBI is catalyzed by the gene products of the bzaA-bzaB-cobT-bzaC-bzaD-bzaE operon, which promote the formation of DMBI with 5-hydroxybenzimidazole, 5-methoxybenzimidazole and 5-methoxy-6-methylbenzimidazole as intermediates. This route was described in the obligate anaerobic bacteria Eubacterium limosum [39] and Acetobacterium woodii [34].

4. Microbial Production of Vitamin B12: Bioprocess Optimization for Cyanocobalamin Production

The demand for cobalamin by the food, beverage, dietary and nutraceutical industries has increased sharply in recent years due to the increased health awareness of the general population as well as the growing popularity of alternative diets, such as vegan and vegetarian diets. For this reason, many efforts have been made in strain and process optimization for cyanocobalamin production over the years [1,40].
Besides the cobalamin forms already mentioned, AdoCbl, MetCbl and CNCbl, there are many other cobamides with different lower axial ligands that act as key cofactors for corrinoid-dependent enzymes that are important, for example, for gut microbiota [41,42]. Despite their importance, this review is focused only on cyanocobalamin, the form that can be absorbed and used by humans and which is currently produced industrially.
Historically, the microorganisms used for cobalamin production at industrial scale were strains with high natural productivity, mainly different strains of P. freudenreichii and P. denitrificans, as well as related strains, such as Pseudomonas nitroreducens and E. casida [1,40].
For many years, a common strategy to improve these strains has been the usage of random mutagenesis techniques to increase vitamin B12 productivity or resistance to toxic intermediates present in media [43]. Nevertheless, overexpression of genes involved in cobalamin biosynthesis [44], heterologous expression of foreign genes [45] and downregulation [46] of several genes have also generated better producer strains. Furthermore, it is worth noting the appearance of new productive strains with promising results, such as B. megaterium [47] and Acetobacter pasteurianus [48], and the heterologous expression of the biosynthetic pathway in other well-known cell platforms, such as E. coli, the later extensively reviewed in Fang et al.’s 2017 study [40]. Recently, Balabanova and co-workers have extensively reviewed the genetic and biosynthetic regulation as well as the genetic tools that have been used with the aim of improving cobalamin production in different cell factories [36].
In contrast, there are also many examples of advances in vitamin B12 microbial production by bioprocess optimization. Table 1 summarizes the most relevant innovations performed at a bioprocess level for increased Cbl production and new strategies for Cbl production in new platforms or media. Studies focused on increased production via genetic engineering of known strains are not presented because the objective of this section is to provide an update on the main bioprocess innovations for biotechnological cobalamin production. A summary of culture conditions, media specifications and volumetric productions and productivities is included.
Overall, sharp differences in cobalamin production can be found amongst different producing microorganisms. In this sense, volumetric productions and productivities obtained with P. denitrificans are clearly superior to the ones obtained with other producers, while P. freudenreichii productions vary widely between strains and culture conditions. In the case of the latter, strategies based on decreasing the propionic acid inhibitory effect seem to be the most effective.

4.1. Microbial Production in Pseudomonas denitrificans

P. denitrificans is a Gram-negative bacterium that uses the aerobic biosynthetic pathway to produce vitamin B12. Despite not having a Generally Recognized as Safe (GRAS) status, P. denitrificans is currently the main vitamin B12 producer used by industrial manufactures, such as Sanofi in Europe [74] or the Huarong Pharmacy Corporation in China.
On one hand, the Sanofi strain was originally generated by a combination of random mutagenesis and molecular biology techniques and, although no official information about its volumetric production is available, taking into consideration other aerobic strains, it is tempting to speculate that it may produce around 200–300 mg/L [72]. The optimized strain was originated from a natural, high-producing strain known as MB-580, first described and patented in 1962 (US3018225A). Over several years, the French company Rhône-Poulenc amplified several of the cob genes involved in vitamin B12 biosynthesis until certain high-producing strains were created—SBL27 and, eventually, SC510 [26]. Sanofi, former Rhône-Poulenc, is now the main European vitamin B12 manufacturer.
The dominant worldwide producers of vitamin B12 on the market are, however, based in China and include the North China Pharmaceutical Company, the Henan Luyuan Pharmaceutical Company, the Hebei Yuxing Bio-Engineering Company and the Chinese CSPC Huarong Pharmaceutical Company, with a combined reported vitamin B12 production in 2020 of approximately 31.41 tons and an estimated value of USD 339.8 million [75]. The origin of the strains used in their industrial productions is not precisely known but assumed to be an aerobic strain due to different publications from research groups related to the Huarong Pharmaceutical Company [69,73,76], and the latest patents on bioprocess optimization with P. denitrificans presented in China claim volumetric productions of up to 281 mg/L (see Table 2).
Besides genetic modifications, vitamin B12 productivity improvement in P. denitrificans has also been achieved with culture media optimization and changes in bioprocessing conditions. For example, the effects of trace elements in media, pH, dissolved oxygen control and the addition of several supplements have been tested. In this sense, the addition of Zn2+ has been reported to have a significant positive effect on the synthesis of ALA and PBG, two of the main precursors of cobalamin, while supplementation with Co2+ and DMBI, the base that is incorporated into the nucleotide loop, positively affects production [77]. Optimization of the initial amounts of these three compounds by design of experiments led to a 13% increase in cobalamin production [77].
Media composition affected the pH stability of cultures and showed a significant effect on vitamin production. In order to better control pH, a feeding strategy with glucose as carbon source and betaine as methyl donor was developed and was found to be beneficial for vitamin production when applied to 120 m3 bioreactor cultures [69,73,76]. Moreover, although it is well known that betaine acts as a methyl donor for vitamin B12 biosynthesis [78] and enhances the formation of several key intermediates, such as ALA, glutamate, glycine and methionine [71], high concentrations of betaine can also inhibit cell growth [71,76]. Therefore, a proper betaine feeding strategy was further developed to balance the negative effect on cell growth and the positive effect on cobalamin production and was later successfully implemented at industrial scale [76].
Oxygen transfer rate (OTR) has also been a major subject of bioprocess optimization in P. denitrificans. Higher OTRs during initial culture stages enhance cell growth, while lower OTRs in later stages were found to be critical for higher productivity [69]. Later studies revealed that the increased production observed in lower oxygenation conditions can be related to alterations in cell morphology, stimulating change from the cell growth phase to an elongation state that presents higher vitamin B12 production [70]. Taking this into consideration, several multi-step dissolved oxygen control strategies were developed, in which aeration and agitation were gradually reduced until dissolved oxygen values fell below 2%, obtaining an improvement in production around 17% [69,73]. Furthermore, the addition of respiratory chain inhibitors, such as rotenone, could also enhance vitamin production despite a detrimental impact on cell growth [67].
Finally, different carbon and nitrogen sources, such as glucose, maltose syrup, beet molasses and corn steep liquor, have been tested as cheaper alternatives to more expensive refined sucrose and glucose. Some of these compounds could negatively affect pH stability and therefore the final vitamin production [68]. Nevertheless, a combination of maltose syrup, corn steep liquor and betaine has been reported as a successful and cheaper alternative to the traditional media compositions [72].

4.2. Microbial Production in Propionibacterium freudenreichii

P. freudenreichii strains comprise Gram-positive rod-shaped bacteria named after their capacity to synthesize large quantities of propionic acid by the Wood–Werkman pathway. In contrast to aerobic vitamin B12 producers, P. freudenreichii has the advantage of GRAS status having been granted by the FDA and Qualified Presumption of Safety (QPS) status granted by the EFSA.
Some genetic engineering approaches were tested in P. freudenreichii to obtain higher amounts of vitamin B12. For example, the overexpression of some of the main genes involved in cobalamin synthesis [44] and a genome shuffling approach [79] were reported to improve cobalamin production. However, the main industrial strains were usually obtained by random mutagenesis using different mutagenic agents, such as UV light or chemical compounds, to obtain better cobalamin producers. In P. freudenreichii, these high-yield strains usually present higher tolerance and resistance to propionic acid [43].
P. freudenreichii are facultative anaerobic strains that follow the anaerobic biosynthetic route for cobalamin production. Despite their only producing high cobalamin yields at very low-oxygen conditions, oxygen is needed for DMBI synthesis and its attachment to the corrinic ring [80]. For this reason, the culture is usually divided into two stages: a first stage in which the cells are cultured in complete anaerobic conditions and a second stage, usually after 72–96 h of cultivation [59,62,80], in which gentle aeration is provided by agitation to generate the microaeration needed for DMBI synthesis and cobalamin production [74].
The GRAS status of these vitamin B12 producers allowed the expansion of their market scope by allowing their direct use in the production of food products. In this sense, in situ food fortification with P. freudenreichii has been successfully tested using food-like media, such as in cheese-like propionic medium or whey-based liquid medium [62,64], cereal matrices [63] and in situ fortification of tempeh [81]. Although final cell densities and reported production levels are low compared to other, traditional media, in the context of food fortification, it allows an increase in cobalamin content using non-traditional sources and the achievement of the recommended daily vitamin B12 consumption levels with only small amounts of fermented products [64].
As mentioned before, these bacteria have the ability to produce large quantities of propionic acid, which eventually becomes toxic and limits cell growth [52]. Therefore, several bioprocess optimization strategies for decreasing propionic accumulation have been tested. In particular, in situ product removal (ISPR) techniques have shown promising results for the simultaneous production of propionic acid and vitamin B12. Among ISPR techniques, the use of expanded-bed adsorption bioreactors (EBABs) with high biocompatibility resins, such as ZGA330, has been reported to support vitamin B12 volumetric production levels between 40 mg/L and 60 mg/L [52]. In EBABs, adsorption occurs when the column is expanded, allowing the culture to pass through the chromatographic column without clogging, while propionic acid is retained in the resin [54]. Different culture conditions [54], carbon and nitrogen sources [51] and the addition of media supplements, such as DMBI [53], have been tested for the simultaneous improvement of propionic acid and vitamin B12 production. In an EBAB system, the combination of glucose and glycerol [54] and corn stalk hydrosylates [51] have proven to be efficient carbon sources, with reported volumetric CNCbl production levels of 43.2 mg/L and 47.6 mg/L, respectively.
Another interesting approach to decrease propionic acid concentration is the co-fermentation of P. freudenreichii with other microorganisms capable of metabolizing propionic acid. For example, the co-culture of P. freudenreichii and Ralstonia eutropha showed an improved cobalamin production from 6.73 mg/L to almost 19 mg/L [57]. Moreover, co-fermentation has also been successfully applied not only to reduce propionic acid but also to either produce more than one product simultaneously or to fortify other cell cultures. Simultaneous production of both folate and vitamin B12 was achieved with the co-cultivation of P. freudenreichii and Lactobacillus plantarum (currently named Lactiplantibacillus plantarum [82]) [55], and a co-fermentation of a Basidiomycota strain plus P. freudenreichii has been recently patented to simultaneously produce vitamin D and B12 [83]. A food fortification example would be the in situ vitamin B12 production in bread dough performed in whey-based media with the co-cultivation of P. freudenreichii and Lactobacillus brevis (currently named Levilactobacillus brevis [82]) to ensure microbial safety and stability [56].
Supplementation with cobalamin precursors is another common strategy for increasing productivity. The addition of common precursors and needed compounds, such as ALA and Co2+, has often been described as beneficial for vitamin production [1]. Although all P. freudenreichii strains are capable of synthetizing DMBI on their own, the biosynthesis of this base is low. Moreover, DMBI formation is not possible in strictly anaerobic conditions, as oxygen is needed for its synthesis [37]. If the availability of DMBI is restricted, the active form of vitamin B12 is not formed, and the cells begin to accumulate incomplete forms, such as cobinamide or pseudovitamin B12. Thus, the addition of DMBI or even DMBI precursors, such as Riboflavin or Nicotiamide, has been consistently reported as a positive factor in cobalamin production [1,40,53,60,62,64]. In addition, other groups have found that the addition of vitamin B12 analogues can decrease feedback inhibition and increase cobalamin production [50].
Finally, P. freudenreichii cultures are also interesting in industrial settings for their ability to grow in a wide range of complex carbon and nitrogen sources and even waste and spent media, such as molasses [84], crude glycerol [61], waste frying sunflower oil [58], tomato pomace [85], liquid acid protein residue of soybean [86] and vegetable juice spent media [87].

5. Vitamin B12 Downstream Processing and Post-Modification Strategies

Recovery of vitamin B12 is a well-described process and, to the best of the authors’ knowledge, has remained unchanged during the past decades at industrial scale (see Figure 3 for a classical bioprocess scheme). Briefly, culture broth is subjected to several separation and purification steps (including extraction, filtration and adsorption processes) which impact on overall process yield and feasibility. Classical downstream processing starts with a biomass concentration to significantly reduce the volume, normally performed by centrifugation. Nevertheless, depending on the bioprocess, Cbl can also be found extracellularly, so purification may start from whole broth.
Either way, all species of corrinoids are extracted by heating at 80–120 °C and a pH of 6.5–8.5 for 10–30 min. Cyanidation can be performed during the extraction process or after the initial filtration and adsorption steps [74,88]. In both cases, the different corrinoids are transformed into CNCbl by the addition of potassium cyanide or thiocyanate. This process is usually performed in the presence of sodium nitrite and heat [80].
Later, CNCbl solution is subsequently clarified by one or more filtration (microfiltration and/or nanofiltration) and adsorption (XAD resin) processes. If the produced Cbl is directed to animal feed, the vitamin solution is often treated with zinc chloride and precipitated with organic solvents, such as acetone, to obtain the final product [89]. When greater purity is required, for example, for pharmaceutical uses, further adsorption steps with different resins (e.g., IRA, Alumina) are often needed to obtain a pure final product. Figure 3 represents a classical bioprocess to obtain highly pure CNCbl.
Once vitamin B12 is purified, it may undergo different post-modifications to be used as a food supplement or oral pharmaceutical in order to enhance its bioavailability. Protecting these compounds can be especially interesting in cases of a non-functional intrinsic factor, which causes very low Cbl bioavailability [90,91]. In this sense, several techniques have been developed to protect oral supplements against specific conditions found in the gastrointestinal environment [92]. Among them, microencapsulation, which is already widely used in pharmaceutical and cosmetic industries [93], has proved to improve vitamin B12 stability using either food-grade W1/O/W2 emulsions [94,95], liposomes [96] or different food-grade encapsulating agents, such as chitosan, arabic gum, sodium alginate, carrageenan, maltodextrin, modified starch, cyanobacterial extracellular polymeric, xanthan and pectin [97,98]. Moreover, Fidaleo and co-workers have recently reviewed nanocarrier usage as a promising nanotechnology that may enable vitamin B12 therapies to be improved, reducing side effects and overall costs as well as ameliorating the quality of patient lives [99].

6. Patents—State of the Art

Research in cobalamin production has been extensively patented since its very beginning, with thousands of patents being published, although most of them are no longer active. Due to the large number of publications and the fact that nowadays most of the production and industrial advances are being made in China, providing a comprehensive list of all the currently active and used patents is difficult and beyond the scope of this review. Instead, Table 2 aims to provide a historical overview of some of the most important and relevant patents for the current industrial strains. We include the state of each patent—as expired, abandoned, or active—in addition to the main innovations claimed and, if available, volumetric production figures.
In 1962, one of the first relevant patents related to the subject after the discovery of the extrinsic factor was US3018225A [100], where the discovery of a natural, high-producing strain (P. denitrificans MB580) was described. This strain was extensively researched and many high-producing strains, such as SC510, were obtained through genetic engineering approaches, as described in US20060019352A1 [101]. In fact, researchers associated with Rhône-Poulenc used MB580 and its derived strains to study the genes behind aerobic Cbl biosynthesis and presented the complete aerobic biosynthetic pathway in 1990 [26]. Nowadays, the precise aerobic strains used for industrial cobalamin production are not known but are thought to be closely related to SC510. More recent aerobic strain-related patents cover all stages of bioprocess development: (i) screening and identification of new producer strains (CN111254173 A [102]), (ii) media and bioprocess optimization (CN108949866 A [103], CN110205350 A [104], CN109837320 A [105]) as well as (iii) downstream processing (CN111808158 A [106]).
On the other hand, most of the earliest anaerobic- and P. freudenreichii-related patents were focused on strain optimization for CNCbl production. In this sense, one of the most significant early patents is US4544633A [43], where the generation of a propionic-resistant producing strain by random mutagenesis is described. Besides strain enhancement, later patents often focused on bioprocess optimization and the use of bed-expanded bioreactors for the simultaneous production of CNCbl and other compounds of interest, such as propionic acid (US6492141B1 [107]). In addition, the possibility of using Cbl-producing strains of P. freudenreichii as probiotics has also been patented (US7427397B2 [108]). Interestingly, the latest patents related to anaerobic strains are focused on either co-cultivation strategies (US9938554 [109], US20200149084A1 [83]) or co-production (CN206828509U [110], IN201827044769 A [111]). The latter patent, IN201827044769 A [111], claims a volumetric production of 76.13 mg/L, which is the maximum production reported for a P. freudenreichii strain.
Finally, there are a number of patents with alternative producing strains, such as B. megaterium (US2576932A [112]), several Lactobacillus strains (WO2011154820A2 [113]), S. meliloti (CN104342390 A [114], CN110804598 A [115]) and even E. coli (WO2019109975A1 [116]). The production levels of most of these microorganisms are quite low compared to the traditional producers, and patents are often focused on strain identification or strain enhancement by genetic engineering or heterologous expression of the main genes involved in Cbl biosynthesis. However, the exception is the S. meliloti strain (CGMCC 9638), which has a vitamin B12 production level in the range of 50–115 mg/L [115].
Table 2. Main patents related to vitamin B12 production.
Table 2. Main patents related to vitamin B12 production.
Patent Application Number (Reference)NameMicroorganism/StrainInnovationVolumetric ProductionYear
Propionibacterium genusUS4544633A [43]
(Expired)
Process for producing vitamin B12 by the fermentation technique, and vitamin B12-producing microorganismP. freudenreichii (IFO 12424, IFO 12391, IFO 12426)Creation of propionic-resistant strains (P. freudenreichii FERM-86 and FERM-87) for enhanced CNCbl production15 mg/L1983
US6492141B1 [107]
(Expired)
Process for the production of vitamin B12P. freudenreichii CBS 929.97O2 effect in production during the anaerobic phase and a "fill and draw" strategy for enhanced production19 mg/L1999
US6187761B1 [117]
(Expired)
Production and use of compositions comprising high concentrations of vitamin B12 activityP. freudenreichii subsp. shermanii and P. denitrificansMethod for producing vitamin B12 and making highly concentrated compositions10 mg/L1999
US7427397B2 [108]
(Expired)
Probiotic PropionibacteriumPropionibacterium jensenii 702Propionibacterium jensenii as a probiotic0.0012 mg/L2004
EP2376644B1 [118]
(Active)
Process for the preparation of
a fermentation broth
Lactobacillus plantarum DSM 22,118 and P. freudenreichii DSM 22120Fermentation media optimization and co-culture for folate and vitamin B12
production
1.07 mg/L2009
CN206828509U [110]
(Active)
A device for producing propionic acid and co-producing vitamin B12 by
semi-continuous fermentation
P. freudenreichiiSimultaneous production of propionic acid and vitamin B12 in a semicontinuous fermentation with propionic acid separation20.12 mg/L2017
US9938554 [109]
(Active)
Co-cultivation of Propionibacterium and yeast.P. freudenreichii (ATCC 6207) and yeast cells (DSM 28271)Co-culture of Propionibacterium and propionic-resistant yeast to decrease the chemical oxygen load (COD) of spent media16 mg/L2018
US20200149084A1 [83]
(Active)
Sequential co-culturing method for producing a vitamin- and protein-rich food productBasidiomycota and
P. freudenreichii
Co-culture of Basidiomycota genus strains and vitamin B12-producing strains
for in situ food fortification
0.0014 mg/L 12020
IN201827044769 A [111]
(Active)
Continuous process for co-production of vitamin B12 and organic acidsP. freudenreichii (ATCC 13673)Co-production of vitamin B12 and organic acids in a continuous fermentation with a single bioreactor76.13 mg/L2020
WO21041759 A1 [119]
(Active)
Modified Propionibacterium and methods of useP. freudenreichii (P. UF 1)Generation of a vitamin B12-overproducing strain by introducing a mutation that decreases the activity of the
cbiMcbl riboswitch
n.d. 22021
Pseudomonas denitrificansUS3018225A [100]
(Expired)
Production of vitamin B12P. denitrificans MB-580A process for vitamin B12 production with a high-yield strain (P. denitrificans MB-580)2.4 mg/L 11962
US20060019352A1 [101]
(Abandoned)
Methods for increasing the production of cobalamins using cob gene expressionP. denitrificansOverexpression of several genes involved in Cob biosynthesis; generation of several overproducing strains, such as SC-51065 mg/L1990
US6156545A [120]
(Expired)
Biosynthesis method enabling the preparation of cobalaminsP. denitrificans G2650Enhanced Cob production by the heterologous overexpression of precursors, such as DMBI and O-phospo-L-threonine7.9 mg/L1996
CN101538599A [121]
(Active)
Method for improving the yield of denitrified pseudomonas vitamin B12P. denitrificans J741Enhance cob production by betaine
addition optimization
177.49 mg/L2008
CN102399845A [122]
(Active)
Vitamin B12 fermentation production control process based on CO2 concentration in tail gasP. denitrificans MB-580Vitamin B12 enhanced production through a carbon dioxide control strategy during fermentation164.6 mg/L2010
CN101748177 A [123]
(Active)
Optimized method for producing vitamin B12 through P. denitrificans fermentation and synthetic mediumP. denitrificansDevelopment and optimization of media and bioprocess conditions for improved vitamin B12 production77 mg/L2010
CN102021214 A [124]
(Active)
Oxygen consumption rate-based vitamin B12 fermentation production control processP. denitrificansVitamin B12 production optimization through an oxygen control strategy171,4 mg/L2011
CN102453740 A [125]
(Active)
Culture medium for producing vitamin B12 by fermenting P. denitrificans and fermentation method thereofP. denitrificansUse of artificial molasses and bioprocess optimization for a more stable fermentation yield198 mg/L2012
CN108949866 A [103]
(Active)
Multi-stage rotating speed regulating policy for improving P. denitrificans fermentation for production of vitamin B12P. denitrificansVitamin B12 production improved by optimization of the culture media and the stirring speed of the bioprocess246 mg/L 12018
CN108913739 A [126]
(Active)
Method for producing vitamin B12 by using P. denitrificans based on pH value controlP. denitrificansImproved vitamin B12 production by optimization of the bioprocess through pH value control248 mg/L2018
CN110205350 A [104]
(Active)
Method for improving the yield of vitamin B12 based on the regulation of ammonia nitrogen indexP. denitrificansA method for improved Cbl production by supplementation with yeast extract controlled by the ammonia nitrogen index167 mg/L 12019
CN109837320 A [105]
(Active)
Method for promoting P. denitrificans to generate vitamin B12P. denitrificansOptimization of media and culture conditions for improved vitamin B12 production198 mg/L2019
CN111808158 A [106]
(Active)
Preparation method of vitamin B12 crude productP. denitrificansDownstream process improvement for AdoCbl extractionn.d. 22020
CN111254173 A [102]
(Active)
Screening method and screening culture medium for bacterial strains for high yield of vitamin B12 produced through fermentation production with P. denitrificansSeveral high-yield strains of P. denitrificansScreening for high-vitamin B12 producing P. denitrificans strains and culture medium screening for high vitamin B12 production281 mg/L 12020
Other producersUS2650896A [127]
(Expired)
Cyanide ions in production of vitamin B12Streptomyces griseusEffects of cyanide ions in B12 productionBiological assay1953
US2576932A [112]
(expired)
Fermentation process to produce vitamin B12B. megaterium B-938Vitamin B12 production with B. megaterium in a nutrient media with sucrose0.45 mg/L1983
US20050227332A1 [128]
(Expired)
Method for producing vitamin B12 from hydrogen-metabolizing methane bacteriumA mesophilic methane bacterium obtained from digested sludgeThe culture is acclimatized in a H2–CO media and grown in an immobilized bed
bioreactor
25.2 mg/L2005
US20060105432A1 [129]
(Abandoned)
Method for the production of vitamin B12B. megaterium DSMZ509Genetically modified B. megaterium strain0.008 mg/L 12006
WO2011154820A2 [113]
(Application granted)
Vitamin B12-producing probiotic bacterial strainsLactobacillus reuteri (DSM 17938, DSM 16143, ATCC 55730)In situ food fortification for increased vitamin B12 production with Lactobacillus reuteri strains0.018 mg/L 12011
CN104342390 A [114]
(Active)
Sinorhizobium meliloti strain and composition and application of Sinorhizobium meliloti strainS. meliloti (CGMCC 9638)A S. melitolli strain capable of producing vitamin B12 and optimization of the bioprocess for vitamin B12 productionAt least 50 mg/L2015
WO2019109975A1 [116]
(Active)
Recombinant strain of Escherichia coli for de novo synthesis of vitamin B12, construction method therefor and application thereofE. coliRecombinant E. coli for the de novo
synthesis of vitamin B12
89 µg/g DCW2019
CN110804598 A [115]
(Active)
Procorrin-2C(20)-methyltransferase mutant and mutant gene and application thereof in preparing vitamin B12Sinorhizobium (CGMCC 9638)Generation of a vitamin B12 overproducer strain by overexpressing the precorrin-2C(20)-methyltransferase gene115 mg/L2020
1 Values were converted to mg/L using the data available from the original publication; 2 n.d.: not determined.

7. Vitamin B12 Market Applications and the State of the Market

The most important market for B12 products is the feed and food industry, where its efficiency and security has been extensively verified [130], although its usage is also extensive in the supplement and pharmaceutical industry.
In the feed and food industry, CNCbl is commonly added to poultry, pig and calf feeds at dosage levels between 10 to 30 mg/t in almost all Europe and the USA [74]. It is also used as an additive in several food products, for example, in cereal, where its organoleptic properties and chemical properties, such as odorlessness, tastelessness and solubility in water, are an advantage for the fortification of several products. Nevertheless, its bright red color can present a challenge to its addition in other foods, such as white bread [88].
Regarding its usage in the supplement industry, vitamin B12 has been gaining relevance in later years, especially with the rise in the popularity of vegetarian and vegan diets [131]. CNCbl is the most used form mainly because of its stability, price, proven safety [22] and its similar efficiency compared to other forms [22,131]. Although there have been some reports of dried algae that contain a significant amount of B12 [132], Cbl is virtually absent in vegetables [131], and the main dietary sources are foods derived from animal products. Although B12 is present in dairy products and eggs (products suitable for vegetarian diets), their quantities are quite low compared with other options (approximately 0.4 μg/100 g in milk and 1.3 µg/100 g in eggs vs. 9.4 μg/100 g in some meats, 8.9 μg/100 g in fish and 52.4 μg/100 in shellfish [132]). This fact, together with the assumed bioavailability of only 50% of all the Cbl obtained from food sources [41] and the losses that can occur during food processing (cooking, exposure to light, pasteurization, etc.) [131], make reaching the recommended daily dietary intake of 2.4 µg a difficult task for those on pure vegetarian diets without vitamin B12 supplements [131].
Vitamin B12 deficiency is also prevalent in low- or middle-income countries with mainly plant-based diets and low meat consumption [133]. Even in high-income countries, though, there are several population groups at high risk of B12 deficiency. This specially affects the elderly, with around 20% of people over 60 suffering from it in the USA and in the UK according to the NIH [134]. In the case of the elderly, deficiency is mostly due to lower intake and a high prevalence of food-bound malabsorption, caused by age-related gastric atrophy and lower IF levels [41,135].
Other high-risk populations are pregnant and lactating women, children, and patients with autoimmune diseases that cause gastric complications, such as atrophic gastritis or decreased stomach acid secretion [132]. In all these cases, a higher daily B12 intake, mainly obtained through supplementation, is recommended.
Although most supplementations are based on CNCbl, in rare cases of cellular trafficking and protein processing alterations caused by rare genetic diseases [136], supplementation with other forms, such as MetCbl or OHCbl, may be required. Additionally, CNCbl supplementation may be unsuitable for supplementation in smoker populations [137,138].
Finally, it should also be noted that it is often preferred to supplement B12 on its own and not as a component of multivitamin tablets because the presence of vitamin C and copper can degrade it and form inactive Cbl by-products [131].
Besides direct supplementation, B12 is also widely used for the fortification of different food products. In this case, CNCbl is again the preferred form due to its higher stability when processed and cooked [132]. B12-fortified products are common in the United States and other countries where, for example, B12-fortified cereals and milk provide a significant amount of the total daily Cbl requirement [132]. Other alternatives, such as flour fortification, have also been considered [139]. In this sense, some of the in situ fortification approaches collected in this review [56,63] may become interesting and valuable alternatives in the future.
Vitamin B12 is also widely used in the pharmacological sector, where, besides CNCbl, other forms, such as OHCbl, AdoCbl and MetCbl, are also produced and distributed due to their higher uptake and more sustained serum levels [74]. Pharmacological B12 is presented in different forms, such as nasal sprays, oral and sublingual products, and even direct injections to treat pernicious anemia, B12 deficiency, cyanide poisoning and lower homocysteine levels. There are also several claims that have been made regarding its positive effect in patients with Alzheimer’s disease and as a stimulant of the immune system, though more evidence is needed to prove these [74,140].
Considering all these different usages and markets, it should not be a surprise that vitamin B12 total worldwide production and market volume have been steadily increasing, although the exact worldwide market values are difficult to obtain due to the scarcity of reliable information. However, it is safe to assume a great increase in overall production in the last decades. In 1989, the overall production was around 3 tons per year [74] and, by 2005, it had already increased to 10 tons and had a market value of approximately EUR 77 million [88]. As mentioned before, production in China in 2020 reached 31.41 tons with a market value of USD 339.48 million [76], while some projections have been made that the vitamin B12 market will reach a total value of USD 410 million by 2027 [141]. The progressive increase in the size of elderly populations, the rise of alternative vegan and vegetarian diets and the scarcity of animal food products are factors that explain this sharp market increase and are also the reasons why the B12 market is expected to continue to grow in the future.

8. Concluding Remarks

From published data, it is clear that industrial vitamin B12 production with Propionibacterium freudenreichii strains presents several challenges and shortcomings that must be surpassed in order for this method to compete against those using aerobic strains. From all the reviewed examples (Table 1 and Table 2), the highest volumetric production with the anaerobic strain was 76 mg/L (IN201827044769 A [111]), clearly inferior to the 250–280 mg/L reported for aerobic strains in different studies (CN108949866 A [103], CN108913739 A [126], CN111254173 A [102]).
However, the singularities of markets in which vitamin B12 is targeted, such as dietary supplements or fortified foods and drinks, need to be taken into consideration. Many final vitamin B12 consumers, besides patients affected by pernicious anemia or other diseases, are vegans or vegetarians and people with high health and ecological awareness. In this scenario, the GRAS status of Propionibacterium freudenreichii and the fact that many producing strains are non-GMO microorganisms are valuable assets that increase its market appeal. For example, in situ fortification strategies can become a future economically viable application for Propionibacterium freudenreichii cultures. This possibility is further reinforced by the promising probiotic properties described for some Propionibacterium freudenreichii strains: microbiota modulation, immunomodulation and the production of several nutraceutical compounds, such as trehalose, naphotic acid and short-chain fatty acids [142].
Moreover, aside from these differentiating traits that can increase the added value for end consumers, the ability of Propionibacterium freudenreichii to synthetize different products besides vitamin B12 (mainly propionic acid and low amounts of trehalose) can also increase its industrial appeal. Currently, most of the worldwide propionic acid production is obtained from crude oil through petrochemical processes and there have been numerous studies that have aimed to find a bio-based alternative production process that would allow this product to be labeled as a “natural preservative” [143]. Therefore, the possibility of a Propionibacterium freudenreichii biorefinery, with simultaneous production and extraction of both propionic acid and vitamin B12, would increase the industrial and commercial feasibility.
Besides Pseudomonas denitrificans and Propionibacterium freudenreichii strains, other possible producers, such as Sinorhizobium meliloti, different Lactobacillus strains and even E. coli (by heterologous expression of the biosynthetic pathway), have also been widely studied. So far, their reported productions are not competitive, making them unsuitable alternatives for industrial CNCbl production. Nevertheless, future strains and strategies may render better production processes which would improve their industrial viability, although their commercial success may be hindered by regulatory constraints and consumer acceptability.
Finally, it should be mentioned that, in its current state, CNCbl production is still suboptimal and has many challenges to overcome to further develop its potential as a cost-effective and valuable industrial bioprocess. The main obstacle is that, even in the higher-producing aerobic strains, such as Pseudomonas denitrificans, volumetric production levels are often around 200–300 mg/L—much lower than those obtained via similar fermentation processes, such as those for vitamin B2. In addition, the fermentation cycles are long and costly, mainly because of the need for expensive media compounds, such as high concentrations of complex nitrogen sources and supplements such as betaine. Supplying enough cobalt to the broth can also be problematic from a cost and an environmental perspective [144].
Further efforts in bioprocessing, downstream and media composition optimization (with cheaper or recycled compounds) should be carried out to increase the economic viability and environmental sustainability of vitamin B12 biotechnological production. However, the main problem, still, is the low productivity of the available producing strains, caused mainly by the tight genetic regulation of Cbl production: the inhibition of the cysG and the cbi operon by the cobalamin riboswitch, as well as other downregulating processes [40,74,144]. Overcoming this limitation may require genetic engineering, which may not be well received by end consumers, mainly vegans or vegetarians, who are very concerned about their diet choices and the usage of GMO organisms.

Author Contributions

Á.C.: literature survey, data analysis and writing of the manuscript; M.C. and T.P. conceptualization and review of the manuscript; A.P.: review of the manuscript and funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants PID2019-104350RB-I00 from MICINN, Spain, and an AGAUR grant 2017SGR-727 from the Generalitat de Catalunya (to A.P.). AC acknowledges a pre-doctoral contract 2018 DI 020 from AGAUR, Generalitat de Catalunya.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

There are no conflict to declare.

References

  1. Martens, H.; Barg, M.; Warren, D.; Jah, J.-H. Microbial Production of Vitamin B12. Appl. Microbiol. Biotechnol. 2002, 58, 275–285. [Google Scholar] [CrossRef] [PubMed]
  2. Minot, G.R.; Murphy, W.P. Treatment of Pernicious Anemia by a Special Diet. J. Am. Med. Assoc. 1926, 87, 1666. [Google Scholar] [CrossRef]
  3. Rickes, E.L.; Brink, N.G.; Koniuszy, F.R.; Wood, T.R.; Folkers, K. Crystalline Vitamin B12. Science 1948, 107, 396–397. [Google Scholar] [CrossRef] [PubMed]
  4. Smith, L. Purification of Anti-Pernicious Anemia Factors from Liver. Nature 1948, 161, 638–639. [Google Scholar] [CrossRef]
  5. Hodgkin, D.C.; Kamper, J.; Lindsey, J.; Mackay, M.; Pickworth, J.; Robertson, J.H.; Shoemaker, C.B.; White, J.G. The Structure of Vitamin B12. I. An Outline of the Crystallographic Investigation of Vitamin B12. Proc. R. Soc. London Ser. A. Math. Phys. Sci. 1957, 242, 228–263. [Google Scholar] [CrossRef]
  6. Dixon, M.M.; Huang, S.; Matthews, R.G.; Ludwig, M. The Structure of the C-Terminal Domain of Methionine Synthase: Presenting S-Adenosylmethionine for Reductive Methylation of B12. Structure 1996, 4, 1263–1275. [Google Scholar] [CrossRef] [Green Version]
  7. Mancia, F.; Keep, N.H.; Nakagawa, A.; Leadlay, P.F.; McSweeney, S.; Rasmussen, B.; Bösecke, P.; Diat, O.; Evans, P.R. How Coenzyme B12 Radicals Are Generated: The Crystal Structure of Methylmalonyl-Coenzyme A Mutase at 2 Å Resolution. Structure 1996, 4, 339–350. [Google Scholar] [CrossRef] [Green Version]
  8. Wuerges, J.; Garau, G.; Geremia, S.; Fedosov, S.N.; Petersen, T.E.; Randaccio, L. Structural Basis for Mammalian Vitamin B12 Transport by Transcobalmin. Proc. Natl. Acad. Sci. USA 2006, 103, 4386–4391. [Google Scholar] [CrossRef] [Green Version]
  9. Mathews, F.S.; Gordon, M.M.; Chen, Z.; Rajashankar, K.R.; Ealick, S.E.; Alpers, D.H.; Sukumar, N. Crystal Structure of Human Intrinsic Factor: Cobalamin Complex at 2.6-Å Resolution. Proc. Natl. Acad. Sci. USA 2007, 104, 17311–17316. [Google Scholar] [CrossRef] [Green Version]
  10. Alam, A.; Woo, J.S.; Schmitz, J.; Prinz, B.; Root, K.; Chen, F.; Bloch, J.S.; Zenobi, R.; Locher, K.P. Structural Basis of Transcobalamin Recognition by Human CD320 Receptor. Nat. Commun. 2016, 7, 12100. [Google Scholar] [CrossRef] [Green Version]
  11. Furger, E.; Frei, D.C.; Schibli, R.; Fischer, E.; Prota, A.E. Structural Basis for Universal Corrinoid Recognition by the Cobalamin Transport Protein Haptocorrin. J. Biol. Chem. 2013, 288, 25466–25476. [Google Scholar] [CrossRef] [Green Version]
  12. Koutmos, M.; Gherasim, C.; Smith, J.L.; Banerjee, R. Structural Basis of Multifunctionality in a Vitamin B12- Processing Enzyme. J. Biol. Chem. 2011, 286, 29780–29787. [Google Scholar] [CrossRef] [Green Version]
  13. Yamada, K.; Gherasim, C.; Banerjee, R.; Koutmos, M. Structure of Human B12 Trafficking Protein CblD Reveals Molecular Mimicry and Identifies a New Subfamily of Nitro-FMN Reductases. J. Biol. Chem. 2015, 290, 29155–29166. [Google Scholar] [CrossRef] [Green Version]
  14. Xu, D.; Feng, Z.; Hou, W.T.; Jiang, Y.L.; Wang, L.; Sun, L.; Zhou, C.Z.; Chen, Y. Cryo-EM Structure of Human Lysosomal Cobalamin Exporter ABCD4. Cell Res. 2019, 29, 1039–1041. [Google Scholar] [CrossRef]
  15. Schubert, H.L.; Hill, C.P. Structure of ATP-Bound Human ATP:Cobalamin Adenosyltransferase. Biochemistry 2006, 45, 15188–15196. [Google Scholar] [CrossRef] [Green Version]
  16. Woodward, R. The Total Synthesis of Vitamin B12. Pure Appl. Chem. 1973, 33, 145–177. [Google Scholar] [CrossRef]
  17. Eschenmoser, A.; Wintner, C.E. Natural Product Synthesis and Vitamin B12. Science 1977, 196, 1410–1420. [Google Scholar] [CrossRef]
  18. Fink, R.G. Coenzyme B12-Based Chemical Precedent for Co-C Bond Homolysis and Other Key Elementary Steps; Krautler, B., Arigoni, D., Golding, B.T., Eds.; Wiley-VCH: Weinheim, Germany, 1998. [Google Scholar]
  19. Hannibal, L.; Axhemi, A.; Glushchenko, A.V.; Moreira, E.S.; Brasch, N.E.; Jacobsen, D.W. Accurate Assessment and Identification of Naturally Occurring Cellular Cobalamins Luciana. Clin. Chem. Lab. Med. 2008, 46, 1739–1746. [Google Scholar] [CrossRef] [Green Version]
  20. Juzeniene, A.; Nizauskaite, Z. Photodegradation of Cobalamins in Aqueous Solutions and in Human Blood. J. Photochem. Photobiol. B Biol. 2013, 122, 7–14. [Google Scholar] [CrossRef]
  21. Hogenkamp, H.P.C.; Vergamini, P.J.; Matwiyoff, N.A. The Effect of Temperature and Light on the Carbon43 Nuclear Magnetic Resonance Spectra of Alkylcorrinoids, Selectively Enriched with Carbon-13. J. Chem. SOC. (A) 1975, 23, 2628–2633. [Google Scholar] [CrossRef]
  22. Obeid, R.; Fedosov, S.N.; Nexo, E. Cobalamin Coenzyme Forms Are Not Likely to Be Superior to Cyano- and Hydroxyl-Cobalamin in Prevention or Treatment of Cobalamin Deficiency. Mol. Nutr. Food Res. 2015, 59, 1364–1372. [Google Scholar] [CrossRef] [PubMed]
  23. Roth, J.R.; Lawrence, J.G.; Bobik, T.A. Cobalamin (Coenzyme B12): Synthesis and Biological Significance. Annu. Rev. Microbiol. 1996, 50, 137–181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Leeper, F.J. The Biosynthesis of Porphyrins, Chlorophylls, and Vitamin B12. Nat. Prod. Rep. 1989, 6, 171–203. [Google Scholar] [CrossRef] [PubMed]
  25. Thibaut, D.; Blanche, F.; Cameron, B.; Crouzet, J.; Debussche, L.; Remy, E.; Vuilhorgne, M. Vitamin B12 Biosynthesis in Pseudomonas denitrificans. In Vitamin B12, and B12-Proteins; Kräutler, B., Arigoni, D., Golding, B.T., Eds.; Wiley-VCH: Weinheim, Germany, 1998; pp. 63–79. [Google Scholar]
  26. Crouzet, J.; Cauchois, L.; Blanche, F.; Debussche, L.; Thibaut, D.; Rouyez, M.C.; Rigault, S.; Mayaux, J.F.; Cameron, B. Nucleotide Sequence of a Pseudomonas Dentrificans 5.4-Kilobase DNA Fragment Containing Five Cob Genes and Identification of Structural Genes Encoding S-Adenosyl-L-Methionine: Uroporphyrinogen III Methyltransferase and Cobyrinic Acid a,c-Diamide Synthase. J. Bacteriol. 1990, 172, 5968–5979. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Stamford, N.P.J.; Duggan, S.; Li, Y.; Alanine, A.I.D.; Crouzet, J.; Battersby, A.R. Biosynthesis of Vitamin B12: The Multi-Enzyme Synthesis of Precorrin-4 and Factor IV. Chem. Biol. 1997, 4, 445–451. [Google Scholar] [CrossRef] [Green Version]
  28. Moore, S.J.; Warren, M.J. The Anaerobic Biosynthesis of Vitamin B12. Biochem. Soc. Trans. 2012, 40, 581–586. [Google Scholar] [CrossRef] [PubMed]
  29. Jaffe, E.K. The Porphobilinogen Synthase Family of Metalloenzymes. Acta Crystallogr. Sect. D Biol. Crystallogr. 2000, 56, 115–128. [Google Scholar] [CrossRef]
  30. Jordan, P.M. The Biosynthesis of 5-Aminolaevulinic Acid and Its Transformation into Uroporphyrinogen III. In New Comprehensive Biochemistry; Krebs, J., Michalak, M., Eds.; Elsevier: Amsterdam, The Netherlands, 1991; Volume 19, pp. 1–66. [Google Scholar]
  31. Raux, E.; Schubert, H.L.; Warren, M.J. Biosynthesis of Cobalamin (Vitamin B12): A Bacterial Conundrum. Cell. Mol. Life Sci. 2000, 57, 1880–1893. [Google Scholar] [CrossRef]
  32. Warren, M.J.; Raux, E.; Schubert, H.L.; Escalante-Semerena, J.C. The Biosynthesis of Adenosylcobalamin (Vitamin B12). Nat. Prod. Rep. 2002, 19, 390–412. [Google Scholar] [CrossRef]
  33. Debussche, L.; Couder, M.; Thibaut, D.; Cameron, B.; Crouzet, J.; Blanche, F. Assay, Purification, and Characterization of Cobaltochelatase, a Unique Complex Enzyme Catalyzing Cobalt Insertion in Hydrogenobyrinic Acid a,c- Diamide during Coenzyme B12 Biosynthesis in Pseudomonas denitrificans. J. Bacteriol. 1992, 174, 7445–7451. [Google Scholar] [CrossRef] [Green Version]
  34. Mathur, Y.; Sreyas, S.; Datar, P.M.; Sathian, M.B.; Hazra, A.B. CobT and BzaC Catalyze the Regiospecific Activation and Methylation of the 5-Hydroxybenzimidazole Lower Ligand in Anaerobic Cobamide Biosynthesis. J. Biol. Chem. 2020, 295, 10522–10534. [Google Scholar] [CrossRef]
  35. Campbell, G.R.O.; Taga, M.E.; Mistry, K.; Lloret, J.; Anderson, P.J.; Roth, J.R.; Walker, G.C. Sinorhizobium Meliloti BluB Is Necessary for Production of 5,6-Dimethylbenzimidazole, the Lower Ligand of B12. Proc. Natl. Acad. Sci. USA 2006, 103, 4634–4639. [Google Scholar] [CrossRef] [Green Version]
  36. Balabanova, L.; Averianova, L.; Marchenok, M.; Son, O.; Tekutyeva, L. Microbial and Genetic Resources for Cobalamin (Vitamin B12) Biosynthesis: From Ecosystems to Industrial Biotechnology. Int. J. Mol. Sci. 2021, 22, 4522. [Google Scholar] [CrossRef]
  37. Deptula, P.; Kylli, P.; Chamlagain, B.; Holm, L.; Kostiainen, R.; Piironen, V.; Savijoki, K.; Varmanen, P. BluB/CobT2 Fusion Enzyme Activity Reveals Mechanisms Responsible for Production of Active Form of Vitamin B12 by Propionibacterium freudenreichii. Microb. Cell Factories 2015, 14, 186. [Google Scholar] [CrossRef] [Green Version]
  38. Nguyen-Vo, T.P.; Ainala, S.K.; Kim, J.R.; Park, S. Analysis, Characterization of Coenzyme B12 Biosynthetic Gene Clusters and Improvement of B12 Biosynthesis in Pseudomonas denitrificans ATCC 13867. FEMS Microbiol. Lett. 2018, 365, fny211. [Google Scholar] [CrossRef]
  39. Hazra, A.B.; Han, A.W.; Mehta, A.P.; Mok, K.C.; Osadchiy, V.; Begley, T.P.; Taga, M.E. Anaerobic Biosynthesis of the Lower Ligand of Vitamin B12. Proc. Natl. Acad. Sci. USA 2015, 112, 10792–10797. [Google Scholar] [CrossRef] [Green Version]
  40. Fang, H.; Kang, J.; Zhang, D. Microbial Production of Vitamin B12: A Review and Future Perspectives. Microb. Cell Fact. 2017, 16, 15. [Google Scholar] [CrossRef] [Green Version]
  41. Sobczyńska-Malefora, A.; Delvin, E.; McCaddon, A.; Ahmadi, K.R.; Harrington, D.J. Vitamin B12 Status in Health and Disease: A Critical Review. Diagnosis of Deficiency and Insufficiency–Clinical and Laboratory Pitfalls. Crit. Rev. Clin. Lab. Sci. 2021, 58, 399–429. [Google Scholar] [CrossRef]
  42. Hardlei, T.F.; Obeid, R.; Herrmann, W.; Nexo, E. Cobalamin Analogues in Humans: A Study on Maternal and Cord Blood. PLoS ONE 2013, 8, e61194. [Google Scholar] [CrossRef] [Green Version]
  43. Kojima, I. Process for Producing Vitamin B12 by the Fermentation Technique, and Vitamin B12-Producing Microorganism. U.S. Patent 4,544,633, 1 October 1985. [Google Scholar]
  44. Piao, Y.; Yamashita, M.; Kawaraichi, N.; Asegawa, R.; Ono, H.; Murooka, Y. Production of Vitamin B12 in Genetically Engineered Propionibacterium freudenreichii. J. Biosci. Bioeng. 2004, 98, 167–173. [Google Scholar] [CrossRef]
  45. Piao, Y.; Kiatpapan, P.; Yamashita, M.; Murooka, Y. Effects of Expression of HemA and HemB Genes on Production of Porphyrin in Propionibacterium freudenreichii. Appl. Environ. Microbiol. 2004, 70, 7561–7566. [Google Scholar] [CrossRef] [Green Version]
  46. Biedendieck, R.; Malten, M.; Barg, H.; Bunk, B.; Martens, J.H.; Deery, E.; Leech, H.; Warren, M.J.; Jahn, D. Metabolic Engineering of Cobalamin (Vitamin B12) Production in Bacillus Megaterium. Microb. Biotechnol. 2010, 3, 24–37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Mohammed, Y.; Lee, B.; Kang, Z.; Du, G. Development of a Two-Step Cultivation Strategy for the Production of Vitamin B12 by Bacillus Megaterium. Microb. Cell Factories 2014, 13, 102. [Google Scholar] [CrossRef] [Green Version]
  48. Bernhardt, C.; Zhu, X.; Schütz, D.; Fischer, M.; Bisping, B. Cobalamin Is Produced by Acetobacter Pasteurianus DSM 3509. Appl. Microbiol. Biotechnol. 2019, 103, 3875–3885. [Google Scholar] [CrossRef]
  49. Gu, Q.; Zhang, C.; Song, D.; Li, P.; Zhu, X. Enhancing Vitamin B12 Content in Soy-Yogurt by Lactobacillus Reuteri. Int. J. Food Microbiol. 2015, 206, 56–59. [Google Scholar] [CrossRef]
  50. Thirupathaiah, Y.; Rani, C.S.; Reddy, M.S.; Venkateswar Rao, L. Effect of Chemical and Microbial Vitamin B12 Analogues on Production of Vitamin B12. World J. Microbiol. Biotechnol. 2012, 28, 2267–2271. [Google Scholar] [CrossRef]
  51. Wang, P.; Shen, C.; Li, L.; Guo, J.; Cong, Q.; Lu, J. Simultaneous Production of Propionic Acid and Vitamin B12 from Corn Stalk Hydrolysates by Propionibacterium freudenreichii in an Expanded Bed Adsorption Bioreactor. Prep. Biochem. Biotechnol. 2020, 50, 763–767. [Google Scholar] [CrossRef]
  52. Wang, P.; Wang, Y.; Liu, Y.; Shi, H.; Su, Z. Novel in Situ Product Removal Technique for Simultaneous Production of Propionic Acid and Vitamin B12 by Expanded Bed Adsorption Bioreactor. Bioresour. Technol. 2012, 104, 652–659. [Google Scholar] [CrossRef]
  53. Wang, P.; Zhang, Z.; Jiao, Y.; Liu, S.; Wang, Y. Improved Propionic Acid and 5,6-Dimethylbenzimidazole Control Strategy for Vitamin B12 Fermentation by Propionibacterium freudenreichii. J. Biotechnol. 2015, 193, 123–129. [Google Scholar] [CrossRef]
  54. Wang, P.; Jiao, Y.; Liu, S. Novel Fermentation Process Strengthening Strategy for Production of Propionic Acid and Vitamin B12 by Propionibacterium freudenreichii. J. Ind. Microbiol. Biotechnol. 2014, 41, 1811–1815. [Google Scholar] [CrossRef]
  55. Hugenschmidt, S.; Schwenninger, S.M.; Lacroix, C. Concurrent High Production of Natural Folate and Vitamin B12 Using a Co-Culture Process with Lactobacillus Plantarum SM39 and Propionibacterium freudenreichii DF13. Process Biochem. 2011, 46, 1063–1070. [Google Scholar] [CrossRef]
  56. Xie, C.; Coda, R.; Chamlagain, B.; Varmanen, P.; Piironen, V.; Katina, K. Co-Fermentation of Propionibacterium freudenreichiiand Lactobacillus Brevisin Wheat Bran for in Situproduction of Vitamin B12. Front. Microbiol. 2019, 10, 1541. [Google Scholar] [CrossRef] [PubMed]
  57. Miyano, K.I.; Ye, K.; Shimizu, K. Improvement of Vitamin B12 Fermentation by Reducing the Inhibitory Metabolites by Cell Recycle System and a Mixed Culture. Biochem. Eng. J. 2000, 6, 207–214. [Google Scholar] [CrossRef]
  58. Hajfarajollah, H.; Mokhtarani, B.; Mortaheb, H.; Afaghi, A. Vitamin B12 Biosynthesis over Waste Frying Sunflower Oil as a Cost Effective and Renewable Substrate. J. Food Sci. Technol. 2015, 52, 3273–3282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Pillai, V.V.; Prakash, G.; Lali, A.M. Growth Engineering of Propionibacterium freudenreichii Shermanii for Organic Acids and Other Value-Added Products Formation. Prep. Biochem. Biotechnol. 2018, 48, 6–12. [Google Scholar] [CrossRef] [PubMed]
  60. Wang, P.; Wang, Y.; Su, Z. Improvement of Adenosylcobalamin Production by Metabolic Control Strategy in Propionibacterium freudenreichii. Appl. Biochem. Biotechnol. 2012, 167, 62–72. [Google Scholar] [CrossRef] [PubMed]
  61. Kośmider, A.; Białas, W.; Kubiak, P.; Drozdzyńska, A.; Czaczyk, K. Vitamin B12 Production from Crude Glycerol by Propionibacterium freudenreichii ssp. Shermanii: Optimization of Medium Composition through Statistical Experimental Designs. Bioresour. Technol. 2012, 105, 128–133. [Google Scholar] [CrossRef] [PubMed]
  62. Chamlagain, B.; Deptula, P.; Edelmann, M.; Kariluoto, S.; Grattepanche, F.; Lacroix, C.; Varmanen, P.; Piironen, V. Effect of the Lower Ligand Precursors on Vitamin B12 Production by Food-Grade Propionibacteria. LWT-Food Sci. Technol. 2016, 72, 117–124. [Google Scholar] [CrossRef] [Green Version]
  63. Chamlagain, B.; Sugito, T.A.; Deptula, P.; Edelmann, M.; Kariluoto, S.; Varmanen, P.; Piironen, V. In Situ Production of Active Vitamin B12 in Cereal Matrices Using Propionibacterium freudenreichii. Food Sci. Nutr. 2018, 6, 67–76. [Google Scholar] [CrossRef]
  64. Deptula, P.; Chamlagain, B.; Edelmann, M.; Sangsuwan, P.; Nyman, T.A.; Savijoki, K.; Piironen, V.; Varmanen, P. Food-like Growth Conditions Support Production of Active Vitamin B12 by Propionibacterium freudenreichii 2067 without DMBI, the Lower Ligand Base, or Cobalt Supplementation. Front. Microbiol. 2017, 8, 368. [Google Scholar] [CrossRef] [Green Version]
  65. Liu, J.; Liu, Y.; Wu, J.; Fang, H.; Jin, Z.; Zhang, D. Metabolic Profiling Analysis of the Vitamin B12 Producer Propionibacterium freudenreichii. Microbiologyopen 2021, 10, e1199. [Google Scholar] [CrossRef]
  66. Zhang, Y.; Li, X.; Wang, Z.; Wang, Y.; Ma, Y.; Su, Z. Metabolic Flux Analysis of Simultaneous Production of Vitamin B12 and Propionic Acid in a Coupled Fermentation Process by Propionibacterium freudenreichii. Appl. Biochem. Biotechnol. 2021, 193, 3045–3061. [Google Scholar] [CrossRef]
  67. Cheng, X.; Chen, W.; Peng, W.; Li, K. Improved Vitamin B12 Fermentation Process by Adding Rotenone to Regulate the Metabolism of Pseudomonas denitrificans. Appl. Biochem. Biotechnol. 2014, 173, 673–681. [Google Scholar] [CrossRef]
  68. Li, K.T.; Liu, D.H.; Li, Y.L.; Chu, J.; Wang, Y.H.; Zhuang, Y.P.; Zhang, S.L. An Effective and Simplified PH-Stat Control Strategy for the Industrial Fermentation of Vitamin B12 by Pseudomonas denitrificans. Bioprocess Biosyst. Eng. 2008, 31, 605–610. [Google Scholar] [CrossRef]
  69. Wang, Z.; Wang, H.; Li, Y.; Chu, J.; Huang, M.; Zhuang, Y.; Zhang, S. Improved Vitamin B12 Production by Step-Wise Reduction of Oxygen Uptake Rate under Dissolved Oxygen Limiting Level during Fermentation Process. Bioresour. Technol. 2010, 101, 2845–2852. [Google Scholar] [CrossRef]
  70. Wang, Z.; Shi, H.; Wang, P. The Online Morphology Control and Dynamic Studies on Improving Vitamin B12 Production by Pseudomonas denitrificans with Online Capacitance and Specific Oxygen Consumption Rate. Appl. Biochem. Biotechnol. 2016, 179, 1115–1127. [Google Scholar] [CrossRef]
  71. Xia, W.; Wei, P.; Kun, C. Interactive Performances of Betaine on the Metabolic Processes of Pseudomonas denitrificans. J. Ind. Microbiol. Biotechnol. 2014, 42, 273–278. [Google Scholar] [CrossRef]
  72. Xia, W.; Chen, W. Industrial Vitamin B12 Production by Pseudomonas denitrificans Using Maltose Syrup and Corn Steep Liquor as the Cost-Effective Fermentation Substrates. Bioprocess Biosyst. Eng. 2015, 38, 1065–1073. [Google Scholar] [CrossRef]
  73. Li, K.T.; Zhou, J.; Cheng, X.; Wei, S.J. Study on the Dissolved Oxygen Control Strategy in Large-Scale Vitamin B12 Fermentation by Pseudomonas denitrificans. J. Chem. Technol. Biotechnol. 2012, 87, 1648–1653. [Google Scholar] [CrossRef]
  74. Vandamme, E.J.; Revuelta, J.L. (Eds.) Industrial Biotechnology of Vitamins, Biopigments, and Antioxidants; Wiley-VCH: Weinheim, Germany, 2016; ISBN 9783527681754. [Google Scholar]
  75. CEIC. China Production: Year to Date: Vitamin E. Available online: https://www.ceicdata.com/en/china/pharmaceuticalproduction-ytd-antiparasitics-vitamins-and-minerals/cn-production-ytd-vitamin-e (accessed on 21 June 2022).
  76. Li, K.T.; Liu, D.H.; Li, Y.L.; Chu, J.; Wang, Y.H.; Zhuang, Y.P.; Zhang, S.L. Improved Large-Scale Production of Vitamin B12 by Pseudomonas denitrificans with Betaine Feeding. Bioresour. Technol. 2008, 99, 8516–8520. [Google Scholar] [CrossRef]
  77. Li, K.T.; Liu, D.H.; Li, Y.L.; Chu, J.; Wang, Y.H.; Zhuang, Y.P.; Zhang, S.L. Influence of Zn2+, Co2+ and Dimethylbenzimidazole on Vitamin B12 Biosynthesis by Pseudomonas denitrificans. World J. Microbiol. Biotechnol. 2008, 24, 2525–2530. [Google Scholar] [CrossRef]
  78. Kusel, J.; Fa, Y.; Demain, A. Betaine Stimulation of Vitamin B12 Biosynthesis in Pseudomonas denitrificans May Be Mediated by an Increase in Activity of δ-Aminolaevulinic Acid Synthase. J. Gen. Microbiol. 1984, 130, 835–841. [Google Scholar] [CrossRef] [Green Version]
  79. Zhang, Y.; Liu, J.Z.; Huang, J.S.; Mao, Z.W. Genome Shuffling of Propionibacterium shermanii for Improving Vitamin B12 Production and Comparative Proteome Analysis. J. Biotechnol. 2010, 148, 139–143. [Google Scholar] [CrossRef] [PubMed]
  80. Gray, M.J.; Escalante-Semerena, J.C. Single-Enzyme Conversion of FMNH2 to 5,6-Dimethylbenzimidazole, the Lower Ligand of B12. Proc. Natl. Acad. Sci. USA 2007, 104, 2921–2926. [Google Scholar] [CrossRef] [Green Version]
  81. Signorini, C.; Carpen, A.; Coletto, L.; Borgonovo, G.; Galanti, E.; Capraro, J.; Magni, C.; Abate, A.; Johnson, S.K.; Duranti, M.; et al. Enhanced Vitamin B12 Production in an Innovative Lupin Tempeh Is Due to Synergic Effects of Rhizopus and Propionibacterium in Cofermentation. Int. J. Food Sci. Nutr. 2018, 69, 451–457. [Google Scholar] [CrossRef]
  82. Zheng, J.; Wittouck, S.; Salvetti, E.; Franz, C.M.A.P.; Harris, H.M.B.; Mattarelli, P.; O’toole, P.W.; Pot, B.; Vandamme, P.; Walter, J.; et al. A Taxonomic Note on the Genus Lactobacillus: Description of 23 Novel Genera, Emended Description of the Genus Lactobacillus Beijerinck 1901, and Union of Lactobacillaceae and Leuconostocaceae. Int. J. Syst. Evol. Microbiol. 2020, 70, 2782–2858. [Google Scholar] [CrossRef]
  83. Frettloeh Martin Sequential Co-Culturing Method for Producing a Vitamin- and Protein-Rich Food Product. U.S. Patent 2020-0149084 A1, 14 May 2020.
  84. Quesada-Chanto, A.; Afschar, A.S.; Wagner, F. Microbial Production of Propionic Acid and Vitamin B12 Using Molasses or Sugar. Appl. Microbiol. Biotechnol. 1994, 41, 378–383. [Google Scholar] [CrossRef]
  85. Haddadin, M.S.Y.; Abu-Reesh, I.M.; Haddadin, F.A.S.; Robinson, R.K. Utilisation of Tomato Pomace as a Substrate for the Production of Vitamin B12—A Preliminary Appraisal. Bioresour. Technol. 2001, 78, 225–230. [Google Scholar] [CrossRef]
  86. Assis, D.A.D.; Matte, C.; Aschidamini, B.; Rodrigues, E.; Záchia Ayub, M.A. Biosynthesis of Vitamin B12 by Propionibacterium freudenreichii subsp. Shermanii ATCC 13673 Using Liquid Acid Protein Residue of Soybean as Culture Medium. Biotechnol. Prog. 2020, 36, e3011. [Google Scholar] [CrossRef]
  87. Gardner, N.; Champagne, C.P. Production of Propionibacterium Shermanii Biomass and Vitamin B12 on Spent Media. J. Appl. Microbiol. 2005, 99, 1236–1245. [Google Scholar] [CrossRef]
  88. Moine, G.; Hohmann, H.-P.; Kurth, R.; Paust, J.; Hähnlein, W.; Pauling, H.; Weimann, B.-J.; Kaesler, B. Vitamins, 6. B Vitamins. In Ullmann’s Encyclopedia of Industrial Chemistry; Wiley-VCH GmbH & Co. KGaA: Weinheim, Germany, 2011. [Google Scholar]
  89. Survase, S.A.; Bajaj, I.B.; Singhal, R.S. Biotechnological Production of Vitamins. Food Technol. Biotechnol. 2006, 44, 381–396. [Google Scholar]
  90. Nielsen, M.J.; Rasmussen, M.R.; Andersen, C.B.F.; Nexø, E.; Moestrup, S.K. Vitamin B12 Transport from Food to the Body’s Cells—A Sophisticated, Multistep Pathway. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 345–354. [Google Scholar] [CrossRef]
  91. Berlin, H.; Berlin, R.; Brante, G. Oral Treatment of Pernicious Anemia with High Doses of Vitamin B12 without Intrinsic Factor. Acta Med. Scand. 1968, 184, 247–258. [Google Scholar] [CrossRef]
  92. Gamboa, J.M.; Leong, K.W. In vitro and in vivo Models for the Study of Oral Delivery of Nanoparticles. Adv. Drug Deliv. Rev. 2013, 65, 800–810. [Google Scholar] [CrossRef] [Green Version]
  93. Dhakal, S.P.; He, J. Microencapsulation of Vitamins in Food Applications to Prevent Losses in Processing and Storage: A Review. Food Res. Int. 2020, 137, 109326. [Google Scholar] [CrossRef]
  94. Matos, M.; Gutiérrez, G.; Iglesias, O.; Coca, J.; Pazos, C. Enhancing Encapsulation Efficiency of Food-Grade Double Emulsions Containing Resveratrol or Vitamin B12 by Membrane Emulsification. J. Food Eng. 2015, 166, 212–220. [Google Scholar] [CrossRef]
  95. Ramalho, M.J.; Loureiro, J.A.; Pereira, M.C. Poly (Lactic-Co-Glycolic Acid) Nanoparticles for the Encapsulation and Gastrointestinal Release of Vitamin B9 and Vitamin B12. ACS Appl. Nano Mater. 2021, 4, 6881–6892. [Google Scholar] [CrossRef]
  96. Bochicchio, S.; Barba, A.A.; Grassi, G.; Lamberti, G. Vitamin Delivery: Carriers Based on Nanoliposomes Produced via Ultrasonic Irradiation. LWT-Food Sci. Technol. 2016, 69, 9–16. [Google Scholar] [CrossRef]
  97. Estevinho, B.N.; Mota, R.; Leite, J.P.; Tamagnini, P.; Gales, L.; Rocha, F. Application of a Cyanobacterial Extracellular Polymeric Substance in the Microencapsulation of Vitamin B12. Powder Technol. 2019, 343, 644–651. [Google Scholar] [CrossRef]
  98. Carlan, I.C.; Estevinho, B.N.; Rocha, F. Study of Microencapsulation and Controlled Release of Modified Chitosan Microparticles Containing Vitamin B12. Powder Technol. 2017, 318, 162–169. [Google Scholar] [CrossRef]
  99. Fidaleo, M.; Tacconi, S.; Sbarigia, C.; Passeri, D.; Rossi, M.; Tata, A.M.; Dini, L. Current Nanocarrier Strategies Improve Vitamin B12 Pharmacokinetics, Ameliorate Patients’ Lives, and Reduce Costs. Nanomaterials 2021, 11, 743. [Google Scholar] [CrossRef]
  100. Long, R.A. Production of Vitamin B12. U.S. Patent 3,018,225, 23 January 1962. [Google Scholar]
  101. Crouzet, J.; Debussche, L.; Schil, S.L.; Thibaut, D. Methods of Increasing the Production of Cobalamins Using Cob Gene Expression. U.S. Patent 2006/0019352 A1, 26 January 2006. [Google Scholar]
  102. Zhendong, L.; Qing, C.; Weikai, X.; Hua, L.; Lulu, Y. Screening Method and Screening Culture Medium for Bacterial Strain for High Yield of Vitamin B12 Produced through Fermentation Production with Pseudomonas denitrificans. CN Patent 111254173 A, 9 June 2020. [Google Scholar]
  103. Yonggan, H.; Yanmao, L.; Hui, L.; Xin, W. Multi-Stage Rotating Speed Regulating Policy for Improving Pseudomonas denitrificans Fermentation for Production of Vitamin B12. CN Patent 108949866 A, 7 December 2018. [Google Scholar]
  104. Wang, J.; Wang, J.; Hanzhong, L.; Yanxia, C.; Mu, Q.; Yingran, L.; Xueran, L.; Jingkun, Z.; Hong, W.; Yuan, Y. Method for Improving Yield of Vitamin B12 Based of Regulation of Ammonia Nitrogen Index. CN Patent 110205350 A, 6 September 2019. [Google Scholar]
  105. Ruiyan, L.; Jiexi, M.; Wei, L.; Caixia, Z.; Fengyu, K. Method for Promoting Pseudomonas denitrificans to Generate Vitamin B12. CN Patent 109837320 A, 4 June 2019. [Google Scholar]
  106. Pengdong, H.; Lizhong, P.; Hongwei, G.; Yi, S.; Qiong, M. Preparation Method of Vitamin B12 Crude Product. CN Patent 111808158 A, 23 October 2020. [Google Scholar]
  107. Hunik, J.H. Process for the Production of Vitamin B12. U.S. Patent 6,492,141 B1, 10 December 2002. [Google Scholar]
  108. Michelle, I.; Adams, C. Probiotic Propionibacterium. U.S. Patent 7.427,397 B2, 23 September 2008. [Google Scholar]
  109. Gregor, K.; Stefan, F.; Mirjan, S.; Hrvoje, P. Co-Cultivation of Propionibacterium and Yeast. U.S. Patent 9,938,554, 10 April 2018. [Google Scholar]
  110. Zhiguo, W.Z.; Guoxia, X.; Liquan, W.; Yunshan, W.S. Device for Producing Propionic Acid and Co-Producing Vitamin B12 by Semi-Continuous Fermentation 2017. CN Patent 206828509 U, 2 January 2018. [Google Scholar]
  111. Mallinath, L.A.; Pillai, V. Continuous Process for Co-Production of Vitamin B12 and Organic Acids. IN Patent 201827044769, 2 October 2020. [Google Scholar]
  112. Garibaldi, J.A.; Kosuke, I.; Lewis, J.C.; Mcginnis, J. Fermentation Process for Production of Vitamin B12. U.S. Patent 2576,932, 4 December 1994. [Google Scholar]
  113. Mogna, G.; Paolo Strozzi, G.; Mogna, L. Vitamin B12 Producing Lactobacillus Reuteri Strains 201. International Patent 2011/154820 A2, 15 December 2011. [Google Scholar]
  114. Dawei, Z.; Miaomiao, X.; Sha, L.; Wenjuan, Z.; Ping, Z.; Huan, F. Sinorhizobium Meliloti Strain and Composition and Application of Sinorhizobium Meliloti Strain. CN Patent 104342390 A, 11 February 2015. [Google Scholar]
  115. Dawei, Z.; Huina, D. Procorrin-2C(20)-Methyltransferase Mutant and Mutant Gene and Application Thereof in Preparing Vitamin B12 2020. CN Patent 110804598 A, 18 February 2020. [Google Scholar]
  116. Zhang, D.; Fang, H. Recombinant Strain of Escherichia Coli for de Novo Synthesis of Vitamin B12, Construction Method Therefor and Application Thereof. International Patent 2019/109975A1, 13 June 2019. [Google Scholar]
  117. Bijl, H.L. Production and Use of Compositions Comprising High Concentrations of Vitamin B12 Activity. U.S. Patent 6,187,761 B1, 13 February 2001. [Google Scholar]
  118. Hugenschmidt, S.; Miescher Schwenninger, S.; Lacroix, C. Process for the Preparation of a Fermentation Broth. EU Patent 2 376 644 B1, 23 April 2014. [Google Scholar]
  119. Mansour, M. Modified Propionibacterium and Methods of Use. International Patent 2021/041759, 4 March 2021. [Google Scholar]
  120. Remy, E.; Examiner, P.; Achutamurthy, P. Biosynthesis Method Enabling the Preparation of Cobalamins. U.S. Patent 6,156,545, 5 December 2000. [Google Scholar]
  121. Zhang, S.; Zhao, Q.; Li, K.; Liu, D.; Hongzhuang, Y.; Wang, Z.; Li, Y. Method for Improving Yield of Denitrified Pseudomonas Vitamin B12. CN Patent 101538599 A, 23 September 2009. [Google Scholar]
  122. Zhang, S.; Chen, X.; Li, Y.; Zhenguo, W.; Xie, L.; Cao, Y.; Tang, L.; Wang, Z.; Zhuang, Y. Vitamin B12 Fermentation Production Control Process Based on CO2 Concentration in Tail Gas. CN Patent 102399845 A, 13 September 2010. [Google Scholar]
  123. Zhang, S.; Zhang, Y.; Wang, Z.; Wang, H.; Zhuang, Y.; Chu, J.; Siliang, Z.; Yiming, Z.; Yinping, Z.; Huiyuan, W.; et al. Optimized Method for Producing Vitamin B12 through Pseudomonas denitrificans Fermentation and Synthetic Medium. CN Patent 101748177 A, 9 December 2008. [Google Scholar]
  124. Wang, H.; Chu, J.; Wang, Z.; Zhuang, Y.; Zhang, S.; Zejian, W.; Huiyan, W.; Yingping, Z.; Siliang, Z.; Ju, C. Oxygen Consumption Rate-Based Vitamin B12 Fermentation Production Control Process. CN Patent 102021214 A, 22 September 2009. [Google Scholar]
  125. Ren, Y.; Leng, X.; Wang, Y.; Qi, N.; Dong, Y.; Xiaohong, L.; Nai, Q.; Yong, R.; Youshan, W.; Yuan, D. Culture Medium for Producing Vitamin B12 by Fermenting Pseudomonas denitrificans and Fermentation Method Thereof. CN Patent 102453740 A, 16 May 2012. [Google Scholar]
  126. Ju, Y.; Yang, H.; Yanmao, L.; Guangyong, Z. Method for Producing Vitamin B12 by Using Pseudomonas denitrificans Based on PH Value Control. CN Patent 108913739 A, 30 November 2018. [Google Scholar]
  127. Mcdaniel, L.E.; Harold, B. Cyanide Ion in Production of Vitamin B12. U.S. Patent 2,650,896, 1 September 1953. [Google Scholar]
  128. Takaaki, M.; Zhenya, Z. Method for Producing Vitamin B12 from Hydrogen-Metabolizing Methane Bacte-Rium. U.S. Patent 2005/0227332 A1, 13 October 2005. [Google Scholar]
  129. Barg, H.; Jahn, D. Method for the Production of Vitamin B12. U.S. Patent 2006/0105432 A1, 18 May 2006. [Google Scholar]
  130. Rychen, G.; Aquilina, G.; Azimonti, G.; Bampidis, V.; Bastos, M.D.L.; Bories, G.; Chesson, A.; Cocconcelli, P.S.; Flachowsky, G.; Gropp, J.; et al. Safety and Efficacy of Vitamin B12 (in the Form of Cyanocobalamin) Produced by Ensifer spp. as a Feed Additive for All Animal Species Based on a Dossier Submitted by VITAC EEIG. EFSA J. 2018, 16, e05336. [Google Scholar] [CrossRef] [Green Version]
  131. Rizzo, G.; Laganà, A.S.; Rapisarda, A.M.C.; la Ferrera, G.M.G.; Buscema, M.; Rossetti, P.; Nigro, A.; Muscia, V.; Valenti, G.; Sapia, F.; et al. Vitamin B12 among Vegetarians: Status, Assessment and Supplementation. Nutrients 2016, 8, 767. [Google Scholar] [CrossRef] [Green Version]
  132. Watanabe, F.; Yabuta, Y.; Tanioka, Y.; Bito, T. Biologically Active Vitamin B12 Compounds in Foods for Preventing Deficiency among Vegetarians and Elderly Subjects. J. Agric. Food Chem. 2013, 61, 6769–6775. [Google Scholar] [CrossRef]
  133. Titcomb, T.J.; Tanumihardjo, S.A. Global Concerns with B Vitamin Statuses: Biofortification, Fortification, Hidden Hunger, Interactions, and Toxicity. Compr. Rev. Food Sci. Food Saf. 2019, 18, 1968–1984. [Google Scholar] [CrossRef] [Green Version]
  134. Oh, S.; Cave, G.; Lu, C. Vitamin B12 (Cobalamin) and Micronutrient Fortification in Food Crops Using Nanoparticle Technology. Front. Plant Sci. 2021, 12, 1451. [Google Scholar] [CrossRef]
  135. Pawlak, R.; Rusher, D.R. A Review of 89 Published Case Studies of Vitamin B12 Deficiency. J. Hum. Nutr. Food Sci. 2013, 1, 1008. [Google Scholar]
  136. Watkins, D.; Rosenblatt, D.S. Inborn Errors of Cobalamin Absorption and Metabolism. Am. J. Med. Genet. Part C Semin. Med. Genet. 2011, 157, 33–44. [Google Scholar] [CrossRef]
  137. Shepherd, G.; Velez, L.I. Role of Hydroxocobalamin in Acute Cyanide Poisoning. Ann. Pharmacother. 2008, 42, 661–669. [Google Scholar] [CrossRef]
  138. Linnell, J.C.; Smith, A.D.; Smith, C.L.; Wilson, M.J.; Matthews, D.M. Effects of Smoking on Metabolism and Excretion of Vitamin B12. BMJ 1968, 2, 215–216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  139. Allen, L.; Rosenberg, I.; Oakley, G.; Omenn, S. Considering the Case for Vitamin B12 Fortification of Flour. Food Nutr. Bull. 2010, 31 (Suppl. S1), S36–S46. [Google Scholar] [CrossRef] [PubMed]
  140. Hamel, J. A Review of Acute Cyanide Poisoning with a Treatment Update. Crit. Care Nurse 2011, 31, 72–82. [Google Scholar] [CrossRef] [PubMed]
  141. Reports and Data Vitamin B12 (Cobalamin) Market to Reach USD 409.7 Million By 2027. Available online: https://www.globenewswire.com/news-release/2020/08/26/2084313/0/en/Vitamin-B12-Cobalamin-Market-To-Reach-USD-409-7-Million-By-2027-Reports-and-Data.html (accessed on 22 April 2022).
  142. Rabah, H.; Rosa do Carmo, F.L.; Jan, G. Dairy Propionibacteria: Versatile Probiotics. Microorganisms 2017, 5, 24. [Google Scholar] [CrossRef] [Green Version]
  143. Zhou, X.; Li, Y. (Eds.) Atlas of Oral Microbiology: From Healthy Microflora to Disease; Elsevier: Amsterdam, The Netherlands, 2015. [Google Scholar]
  144. Acevedo-Rocha, C.G.; Gronenberg, L.S.; Mack, M.; Commichau, F.M.; Genee, H.J. Microbial Cell Factories for the Sustainable Manufacturing of B Vitamins. Curr. Opin. Biotechnol. 2019, 56, 18–29. [Google Scholar] [CrossRef]
Figure 1. Schematical representation of the structure shared by all cobalamin isoforms. The main groups that usually act as the upper ligand are also shown. 5,6-DMBI: 5,6-dimethylbenzimidazole.
Figure 1. Schematical representation of the structure shared by all cobalamin isoforms. The main groups that usually act as the upper ligand are also shown. 5,6-DMBI: 5,6-dimethylbenzimidazole.
Bioengineering 09 00365 g001
Figure 2. Summary of anaerobic and aerobic adenosylcobalamin biosynthesis. Genes encoding the proteins from the aerobic and anaerobic pathways are shown in blue and red, respectively, except for Protein α whose coding gene is not known.
Figure 2. Summary of anaerobic and aerobic adenosylcobalamin biosynthesis. Genes encoding the proteins from the aerobic and anaerobic pathways are shown in blue and red, respectively, except for Protein α whose coding gene is not known.
Bioengineering 09 00365 g002
Figure 3. Classical bioprocess to obtain highly pure Cyanocobalamin. The main CNCbl stream is highlighted in red. Intermediate storage vessels are omitted to simplify the figure. P1 to P11 represent Process 1 to Process 11, respectively. Bioprocess represented using SuperPro Designer® V9 Academic Site Edition, Intelligen, Inc. (Scotch Plains, NJ, USA).
Figure 3. Classical bioprocess to obtain highly pure Cyanocobalamin. The main CNCbl stream is highlighted in red. Intermediate storage vessels are omitted to simplify the figure. P1 to P11 represent Process 1 to Process 11, respectively. Bioprocess represented using SuperPro Designer® V9 Academic Site Edition, Intelligen, Inc. (Scotch Plains, NJ, USA).
Bioengineering 09 00365 g003
Table 1. Summary of reported productions with the industrial cobalamin producing strains.
Table 1. Summary of reported productions with the industrial cobalamin producing strains.
Microorganism/StrainMain Media ComponentsScaleSummary/InnovationVolumetric
Production
Volumetric
Productivity (mg/L/h)
Reference
B. megaterium DSM 319Terrific broth media250 mL shake flaskPrecursor supplementation and pO2 control0.21 mg/L c0.006 mg/L/h c[47]
Lactobacillus reuteri ZJ03Soymilk250 mL shake flaskDifferent carbon source supplementation0.204 mg/L0.003 mg/L/h[49]
P. freudenreichii
subsp. shermanii
NRRL-B-4327, 3523 and NRRL-B-3524
Sodium lactate broth250 mL shake flaskVitamin B12 analogue addition31 mg/L0.51 mg/L[50]
P. freudenreichii CICC 10019Glucose, CSL a7 L stirred tankbioreactorExpanded-bed bioreactor (EBAB) with crop
stark hydrolysates
47.6 mg/L0.18 mg/L/h[51]
P. freudenreichii CICC 10019Glucose, CSL7 L stirred tank
bioreactor
EBAB bioreactor43.4 mg/L0.27 mg/L/h[52]
P. freudenreichii CICC 10019Glucose, CSL1.5 L stirred tank
bioreactor
EBAB bioreactor and
DMBI addition
58.8 mg/L0.59 mg/L/h[53]
P. freudenreichii CICC 10019Glucose/glycerol, CSL5 L stirred tank
bioreactor
EBAB bioreactor, glycerol as carbon source and crop stalk hydrolysate as nitrogen source43 mg/L0.36 mg/L/h[54]
P. freudenreichii DF13Supplemented whey permeate1 L stirred tank
bioreactor
Co-culture with Lactobacillus plantarum SM39 for simultaneous folate and Cbl production0.75 mg/L0.004 mg/L/h[55]
P. freudenreichii DSM 20271//Lactobacillus brevis ATCC 14869Wheat bran doughn.d. bCo-fermentation in wheat bran dough for in situ production of Vitamin B12332 ng/g cn.d. b[56]
P. freudenreichii IFO 12424//Ralstonia eutropha H16 (ATCC17699)Polypeptone, casein,
yeast extract
5 L stirred tank
bioreactor
Cell recycling system and co-culture with Ralstonia eutropha for decreasing propionic acid inhibition8 mg/L c0.14 mg/L/h c[57]
P. freudenreichii PTCC 1674.Tryptone, yeast extract, different carbon sources100 cm3Waste frying sun oil as a carbon source for vitamin B12
production
2.74 mg/L0.02 mg/L/h[58]
P. freudenreichii
subsp. shermanii ATCC 13673
Glucose, yeast extract2 L stirred tank
bioreactor
Inoculum volume, pH control and substrate concentration optimization0.087 mg/L0.002 mg/L/h[59]
P. freudenreichii
subsp. shermanii CICC 10019
Glucose, CSL100 L fermenterAddition of DMBI precisely with Ado-Cbl control strategy39.15 mg/L0.32 mg/L/h[60]
P. freudenreichii
subsp. shermanii
Glycerol, tryptone, casein, DMBI200 mL
shake flask
Media optimization by design of experiments with crude glycerol as the main carbon source4.01 mg/L0.024 mg/L/h[61]
P. freudenreichii
subsp. shermanii
Whey based media20 mL tubesDMBI, Nicotinamide and Riboflavin supplementation5.3 mg/L0.03 mg/L/h[62]
P. freudenreichii
subsp. shermanii
Food-like media
(cereal matrices)
n.d. bPrecursor supplementation in
different cereal-like matrices
1.5 mg/Kg0.009 mg/Kg/h[63]
P. freudenreichii
subsp. shermanii 2067
Cheese-based propionic media/whey-based liquid media50 mL shake flaskProduction in food-like conditions without DMBI addition0.124 mg/L c0.0013 mg/L/h[64]
P. freudenreichii CICC10019Glucose, yeast extract, CSL100 mL flasksMedia optimization by statistical analysis8.32 mg/L0.068 mg/L/h[65]
P. freudenreichii CICC10019Glucose, CSL7 L fermenterMembrane separation-coupled fed-batch fermentation21.6 mg/L0.16 mg/L/h[66]
P. denitrificansMaltose, peptone, betaine250 mL shake flaskAddition of rotenone as a respiration inhibitor for enhanced production54.7 mg/L0.57 mg/L/h[67]
P. denitrificansBeet molasses, sucrose, betaine120 m3 fermenterGlucose-betaine feeding, pH control strategy214.13 mg/L c1.27 mg/L/h c[68]
P. denitrificansGlucose, CSL, betaine120 m3 fermenterStepwise oxygen uptake rate control strategy188 mg/L1.12 mg/L/h[69]
P. denitrificansGlucose, CSL, betaine50 L fermenterEffects of specific oxygen consumption rate on cell morphology and production213.1 mg/L1.88 mg/L/h[70]
P. denitrificansMaltose, peptone, betaine250 mL shake flaskBetaine supplementation58.61 mg/L0.48 mg/L/h[71]
P. denitrificansMaltose syrup, CSL, betaine120 m3 fermenterMaltose syrup and CSL as the main substrates198.27 mg/L1.10 mg/L/h[72]
P. denitrificansGlucose, CSL, betaine120 m3 fermenterpO2 stepwise control198.80 mg/L1.18 mg/L/h[73]
The main microorganism, strain, scale and media compounds are shown as well as a brief summary of the main innovation and the volumetric productions. Volumetric productions are presented in mg/L. Volumetric productivities were calculated using data from the original publications. a CSL: corn steep liquor; b n.d.: not determined; c Values were converted to mg/L or mg/L/h using the data available from the original publication.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Calvillo, Á.; Pellicer, T.; Carnicer, M.; Planas, A. Bioprocess Strategies for Vitamin B12 Production by Microbial Fermentation and Its Market Applications. Bioengineering 2022, 9, 365. https://doi.org/10.3390/bioengineering9080365

AMA Style

Calvillo Á, Pellicer T, Carnicer M, Planas A. Bioprocess Strategies for Vitamin B12 Production by Microbial Fermentation and Its Market Applications. Bioengineering. 2022; 9(8):365. https://doi.org/10.3390/bioengineering9080365

Chicago/Turabian Style

Calvillo, Álvaro, Teresa Pellicer, Marc Carnicer, and Antoni Planas. 2022. "Bioprocess Strategies for Vitamin B12 Production by Microbial Fermentation and Its Market Applications" Bioengineering 9, no. 8: 365. https://doi.org/10.3390/bioengineering9080365

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop